Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer : an open-label comparative cohort trial

Strahlenther Onkol. 2011 Oct;187(10):619-25. doi: 10.1007/s00066-011-2226-6. Epub 2011 Sep 19.

Abstract

Purpose: To evaluate the therapeutic effect of delivering regional hyperthermia (HT) plus chemoradiotherapy (CRT) in patients suffering from locally advanced unresectable pancreatic cancer (LAPC).

Methods: Between January 2000 and December 2008, 68 patients affected by primary (56/68) or recurrent (12/68) LAPC were treated either with CRT alone or CRT plus HT. Radiotherapy (RT) consisted of 3D conformal irradiation of tumor and regional lymph nodes (dose ranged from 30 Gy/10 fractions to 66 Gy/33 fractions). Chemotherapy (CT) consisted of gemcitabine (GEM) alone or in association with either oxaliplatin, cisplatin, or 5-FU. HT was delivered twice a week, concomitant with RT.

Results: In the current study, 60 of the original 68 patients were included. Median overall survival (OS) was 15 months in the HT group versus 11 months in the control group (log-rank test: p = 0.025). HT did not increase CRT toxicity.

Conclusion: HT can be added safely to CRT in LAPC, thus, resulting in slightly prolonged survival in certain cases.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Chemoradiotherapy / adverse effects
  • Chemoradiotherapy / methods*
  • Cohort Studies
  • Combined Modality Therapy / adverse effects
  • Feasibility Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Hyperthermia, Induced / adverse effects
  • Hyperthermia, Induced / methods*
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy*
  • Pancreatic Neoplasms / mortality
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / therapy*
  • Prospective Studies
  • Radiotherapy, Conformal / methods
  • Thermometers